Facebook link Linked In link You Tube link

Interventional Immunology

InterventionalImmunologyVenOnly

Interventional Immunology

Wednesday, June 20 at FOCIS 2018
San Francisco Marriott Marquis

San Francisco, CA

You may add Interventional Immunology to your FOCIS 2018 registration or attend the course only.

button register 45


 

2017 Course Director

QizhiTang carla-greenbaum
Qizhi Tang, PhD
University of California, San Francisco     
Carla Greenbaum, MD
Benaroya Research Insitute

Target Audience/Purpose

The Interventional Immunology course is intended to familiarize practicing physicians with the scientific basis of novel immune therapies, their clinical applications, and possible side-effects and limitations.

Course Objectives

Upon completion of this activity, the participant should be able to:

  • Identify the scientific basis for choosing immunogically related therapeutic targets in various diseases, including organ specific and systemic autoimmunity, allergy, transplant rejection, and cancer.
  • Explain the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice
  • Evaluate the track record of the different therapeutic approaches in different specialties.
  • Recognize the cross-disciplinary lessons that can be learned from the clinical experience with specific interventions including pharmacological issues, limitations in altering disease progression and complications due to immunosuppression (infections, neoplasias).
  • Analyze how a physician should decide to use and choose therapies.

Course Testimonials

Read what past attendees are saying about the Interventional Immunology course:

  • "Attending this course has definitely sharpened my therapeutic skills as a clinical immunologist."
  • "This was an excellent overview of the basic science underpinning current immunological intervention.

Sample Course Agenda

  Wednesday
8:00 - 8:30 am Continental Breakfast
8:30 - 9:15 am Small Molecules to the Rescue: Inhibition of Cytokine Signaling in Immune-mediated Diseases
Massimo Gadina, PhD, National Institutes of Health
9:15 - 10:00 am PD-1 Inhibitors in Cancer Therapy
Adil Daud, MD, University of California, San Francisco
10:15 - 11:00 am Re-directed T Cells as Therapy
Marcela Maus, MD, PhD, Harvard University
11:00 - 11:45 am IL-17 Based Therapies
Frank Nestle, MD, King's College London
12:30 - 1:15 pm
Introduction to Clinical Trials
Carla Greenbaum, MD, Benaroya Research Institute; Anne Lindblad, PhD, EMMES Corporation
1:15 - 1:45 pm IBD Therapies
Jonathan Jacobs, MD, University of California, Los Angeles
1:45 - 5:00 pm Guided Practicum on Clinical Trial Design
Share